Nkarta (NKTX) to Release Earnings on Tuesday

Nkarta (NASDAQ:NKTX) is expected to be posting its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($0.32) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, April 3, 2026 at 4:00 PM ET.

Nkarta Price Performance

NASDAQ NKTX opened at $2.18 on Tuesday. Nkarta has a fifty-two week low of $1.31 and a fifty-two week high of $2.81. The stock has a market capitalization of $154.85 million, a PE ratio of -1.58 and a beta of 0.47. The business has a fifty day moving average price of $2.28 and a two-hundred day moving average price of $2.10.

Insider Activity at Nkarta

In other news, CEO Paul J. Hastings sold 26,046 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $2.07, for a total transaction of $53,915.22. Following the transaction, the chief executive officer directly owned 390,023 shares of the company’s stock, valued at $807,347.61. This represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Invesco Ltd. raised its holdings in shares of Nkarta by 478.4% in the 1st quarter. Invesco Ltd. now owns 69,396 shares of the company’s stock worth $128,000 after acquiring an additional 57,399 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of Nkarta by 300.5% during the first quarter. AQR Capital Management LLC now owns 672,078 shares of the company’s stock valued at $1,237,000 after buying an additional 504,272 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Nkarta by 13.3% during the first quarter. Goldman Sachs Group Inc. now owns 681,068 shares of the company’s stock worth $1,253,000 after buying an additional 80,211 shares in the last quarter. Jane Street Group LLC raised its position in Nkarta by 118.7% in the 1st quarter. Jane Street Group LLC now owns 134,286 shares of the company’s stock valued at $247,000 after buying an additional 852,559 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Nkarta by 0.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,208,378 shares of the company’s stock valued at $2,006,000 after buying an additional 10,065 shares during the last quarter. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently commented on NKTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Nkarta in a research note on Monday, December 29th. Wall Street Zen raised Nkarta from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Nkarta currently has an average rating of “Moderate Buy” and a consensus price target of $13.25.

Nkarta Company Profile

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.